Neurovalens

Executive Summary

Neurovalens is a UK-based health-tech company pioneering non-invasive neurostimulation devices for chronic health conditions. Its flagship product, Modius Sleep, is an FDA-cleared, physician-prescribed device that uses electrical vestibular nerve stimulation (VeNS) to treat chronic insomnia. The company's drug-free approach targets a large market: over 30 million adults in the US suffer from chronic insomnia, and many seek alternatives to pharmacotherapy. Neurovalens has established a clear regulatory pathway with the FDA, positioning itself for commercial scaling. The technology also holds promise for additional indications such as obesity, anxiety, and depression, where VeNS may modulate neural circuits affecting appetite and mood. With a strong IP portfolio and growing clinical evidence, Neurovalens is well-positioned to capture share in the non-pharmacological neurostimulation market, which is projected to exceed $20 billion by 2030. Despite its potential, Neurovalens faces challenges common to early-stage medical device companies. The company remains private, with limited public financial disclosure, making assessment of its revenue and burn rate difficult. Commercial adoption of Modius Sleep depends on physician training, insurance reimbursement, and patient awareness. Reimbursement for insomnia devices is not yet well established, which could slow uptake. Furthermore, competitors like Fisher Wallace and Neuromod are developing similar technologies, intensifying the competitive landscape. Neurovalens must demonstrate robust clinical data beyond insomnia to expand into larger markets. If it successfully executes regulatory approvals and partnerships, the company could achieve significant growth, but execution risk remains moderate.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for Modius Obesity indication60% success
• Q4 2026CE mark approval for Modius Sleep in Europe70% success
• Q2 2026Series B funding round completion75% success